Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
収録刊行物
-
- Annals of Oncology
-
Annals of Oncology 26 (9), 1877-1883, 2015-09
Elsevier BV